Nexstim Future Growth

Future criteria checks 4/6

Nexstim is forecast to grow earnings and revenue by 75.1% and 15.7% per annum respectively while EPS is expected to grow by 75.6% per annum.

Key information

75.1%

Earnings growth rate

75.6%

EPS growth rate

Medical Equipment earnings growth	14.2%
Revenue growth rate	15.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	22 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:5NX - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	14	2	2	3	1
12/31/2025	12	1	2	2	1
12/31/2024	9	0	2	2	1
6/30/2024	9	-1	-2	0	N/A
3/31/2024	9	-1	-3	-1	N/A
12/31/2023	9	-1	-4	-2	N/A
9/30/2023	8	-2	-4	-3	N/A
6/30/2023	6	-3	-4	-3	N/A
3/31/2023	9	-1	-2	-1	N/A
12/31/2022	11	1	0	1	N/A
9/30/2022	11	2	0	2	N/A
6/30/2022	12	3	0	2	N/A
3/31/2022	10	1	-2	0	N/A
12/31/2021	8	-1	-4	-2	N/A
9/30/2021	7	-2	-4	-3	N/A
6/30/2021	6	-4	-4	-3	N/A
3/31/2021	5	-4	-3	-3	N/A
12/31/2020	4	-4	-3	-3	N/A
9/30/2020	4	-4	-4	-4	N/A
6/30/2020	4	-4	-5	-5	N/A
3/31/2020	4	-6	-6	-6	N/A
12/31/2019	3	-7	-8	-7	N/A
9/30/2019	3	-7	-8	-7	N/A
6/30/2019	3	-7	-7	-7	N/A
3/31/2019	3	-7	-7	-6	N/A
12/31/2018	3	-6	-7	-6	N/A
9/30/2018	3	-6	-6	-6	N/A
6/30/2018	3	-6	-6	-6	N/A
3/31/2018	3	-7	N/A	-6	N/A
12/31/2017	3	-7	N/A	-5	N/A
9/30/2017	3	-7	N/A	-5	N/A
6/30/2017	3	-6	N/A	-5	N/A
3/31/2017	3	-6	N/A	-6	N/A
12/31/2016	3	-7	N/A	-7	N/A
9/30/2016	3	-8	N/A	-8	N/A
6/30/2016	3	-9	N/A	-10	N/A
3/31/2016	3	-10	N/A	-10	N/A
12/31/2015	3	-10	N/A	-10	N/A
9/30/2015	3	-10	N/A	-10	N/A
6/30/2015	3	-10	N/A	-11	N/A
3/31/2015	2	-10	N/A	-9	N/A
12/31/2014	2	-10	N/A	-8	N/A
9/30/2014	2	-9	N/A	-6	N/A
6/30/2014	2	-7	N/A	-5	N/A
3/31/2014	2	-6	N/A	-4	N/A
12/31/2013	2	-5	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5NX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: 5NX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 5NX is expected to become profitable in the next 3 years.

Revenue vs Market: 5NX's revenue (15.7% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 5NX's revenue (15.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 5NX's Return on Equity is forecast to be high in 3 years time

Nexstim Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Nexstim Plc Updates Earnings Guidance for the Year 2023

Nexstim Plc Provides Earnings Guidance for the Year 2022

Forecast to breakeven in 2022

Recent updates

Nexstim Plc to Report Fiscal Year 2024 Results on Feb 27, 2025

Nexstim plc Receives Approval from Health Canada for the Marketing and Commercial Distribution of Its NBS 6 System for the Treatment of Major Depressive Disorder

Nexstim Plc Updates Earnings Guidance for the Year 2023

Nexstim Plc, Annual General Meeting, Mar 28, 2024

Nexstim Plc to Report Fiscal Year 2023 Final Results on Mar 06, 2024

Nexstim Plc Releases New System Functionalities for Research Use in Europe

Nexstim Plc to Report Q3, 2023 Results on Oct 27, 2023

Nexstim plc Announces Board Appointments

Nexstim Plc to Report Fiscal Year 2023 Results on Feb 27, 2024

Nexstim plc Provides Overview of Pilot Study Results in Treatment of Severe Depression with Nexstim Nbt®? System At Kuopio University Hospital

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Nexstim Plc, Annual General Meeting, Mar 31, 2023

Nexstim Reports Excellent Treatment Outcomes of over 400 MDD Patients in Patient Registry

Nexstim plc Appoints Tero Weckroth as A New Member of the Nomination Committee

First half 2022 earnings released

Nexstim Plc Provides Earnings Guidance for the Year 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Forecast to breakeven in 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Nexstim Plc Announces Results of the Pilot Study in Chronic Pain Treatment At Helsinki University Hospital

Nexstim Plc Receives System Orders from Existing Hospital Customers in Finland

Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

First half 2021 earnings released: €0.17 loss per share (vs €1.25 loss in 1H 2020)

Nexstim Plc Provides Update on Pilot Study in Chronic Pain Treatment at Helsinki University Hospital

Nexstim Plc Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater Than 50%

Nexstim Plc Granted Authorization for Commercial Distribution of NBS System in Australia

Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder

Nexstim plc Receives Two NBS System Orders from Hospitals in Norway and the Us

Nexstim plc Provides Encouraging Results of the Initial Pilot Study in Severe Depression At Kuopio University Hospital

Full year 2020 earnings released

Revenue beats expectations

German University Hospital Orders Nexstim NBS System with NexSpeech

Rohan Hoare and Tomas Holmberg No Longer Be Available to Nexstim Plc's Board of Directors for the Period 2021-2022

Nexstim plc Receives Three New NBS System Orders

Nexstim Plc Receives Two New NBT® System Purchase Orders in the United States

Nexstim plc Provides an Update on the Pilot Study in Severe Depression At Kuopio University Hospital

Nexstim Plc Receives an Order and Signs Purchase Agreement to Develop Two Prototype Systems Enabling Introduction of Novel Research Tool for Probing and Diagnosing the Brain

Nexstim plc Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus rTMS Treatment of Major Depressive Disorder

Pilot Study for New Depression Treatment Protocol with Nexstim NBT® System Starts in Kuopio University Hospital

Nexstim plc Receives Two Nbs System Upgrade Orders in the United States

Earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies